Indian civil society pushes for ‘Government Use’ compulsory license on MDR-TB Drugs

Source: Lawyers Collective | 12 March 2018

Survivors of drug resistant tuberculosis, health organisations and the TB community in India and across the globe have appealed to the Prime Minister of India to issue a government use compulsory license for two of the essential drugs for Drug-Resistant Tuberculosis (DR-TB) treatment- Bedaquiline and Delamanid to encourage generic competition.

Bedaquiline and Delamanid adult formulations were added to the WHO Essential Medicines List (EML) for TB in 2015, and Delamanid was added to the WHO EML for children in 2017. Continue reading

Posted in Compulsory Licensing, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Health bodies push for compulsory licence for two drugs on MDR-TB

Source: PTI Published: India Today | March 13, 2018

New Delhi: Survivors of drug-resistant tuberculosis, health organisations and the TB community have appealed to Prime Minister Narendra Modi to allow issuance of compulsory licence for two of the essential drugs for drug-resistant TB (DR-TB) treatment so that Indian drug-makers can sell them at affordable prices.

Bedaquiline and Delamanid are recommended by the World Health Organisation (WHO) for DR-TB patients.  Continue reading

Posted in Compulsory Licensing, Patent, Tuberculosis (TB), Uncategorized | Leave a comment

Letter to India’s Prime Minister: Grant Compulsory License for Bedaquiline and Delaminid

57, Tejaswinagar, Dharwad 580002. 0836-2461722
(Registered, independent NGO campaigning for Rational Drug Therapy and Policies)

Date 9th March 2018


The Prime Minister, New Delhi.


Subject;- Granting of CL for Bedaquiline and Delaminid

We the undersigned learn from media report that two important drugs (Bedaquiline and Delaminid manufactured by Janssen of the USA and Otsuka of Japan) needed to treat Drug Resistance Tuberculosis (DR TB) are not available to Indian patients. Both the drug companies are ready to donate the medicines but it well known from previous experiences that such “donations” are only an excuse for the drug companies to tighten the grip over market and thus keep the drug price high. This will only keep the medicines away from the reach of the needy. Unfortunately the drug manufacturing companies are not even ready for voluntary licensing. Continue reading

Posted in Compulsory Licensing, Drug prices, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | 1 Comment

Chile Ministry of Health Takes Next Step Toward Compulsory License on HCV Drugs, Announces Public Health Justifications

by Andrew Goldman, Knowledge Ecology International | 8 March 2018

In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV), as requested by Corporacion Innovarte, Fundacion Renacer, members of the Chilean Congress including Giorgio Jackson, Karla Rubilar, Miguel Angel Alvarado, and Gabriel Boric, and patients in March 2017. The announcement is Ordinario A15 No.1135, and the formal resolution is here.

Continue reading

Posted in Uncategorized | Leave a comment

New Government Report Affirms India’s Patient-First Commitment on Pharma Patents

A government review says it is well within its rights to put Indian patients and the Indian generic pharmaceuticals industry first.

As various countries await the US’s ‘Special 301 report’, where the US government discusses intellectual property negotiations with other countries, , the Indian government has published a report of its on the same topic, affirming its sovereign commitments  to India’s generic drugs industry and healthcare. Continue reading

Posted in Indian Patent Law, Patent, Uncategorized, USTR, USTR 301 report | Leave a comment

Korea counters US’ ‘discriminatory’ drug pricing claim

By Son Ji-hyoung, The Korea Hearld

South Korea has submitted a document hitting back at a claim by a US trade group representing its pharmaceutical industry that Korea’s drug pricing policies favor its domestic industry, ministries said Wednesday.

The document was prepared by the Ministry of Health and Welfare and submitted Thursday to the US Trade Representative, a US counterpart in the bilateral free trade deal, by the Ministry of Trade, Industry and Energy, according to a ministry spokesperson.  Continue reading

Posted in Drug prices, Uncategorized | Leave a comment

Pharmaceutical corporations need to stop free-riding on publicly-funded research

Jason Cone | The Hill 

The White House Council of Economic Advisers recently announced a strategy to curb high drug prices: force “free riding” countries abroad to pay more and watch the prices go down in America.

That’s not how it works; lifesaving medicines aren’t more expensive here because they cost less elsewhere. They’re priced out of reach everywhere because pharmaceutical corporations are charging exorbitant prices simply because they can—and the U.S. government lets them. Continue reading

Posted in Uncategorized | Leave a comment